T6517 |
Golvatinib
|
928037-13-2
|
98%
|
|
Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor ...
|
T4554 |
AG 1406
|
71308-34-4
|
98%
|
|
AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.
|
T6057 |
URMC-099
|
1229582-33-5
|
98%
|
|
URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM)...
|
T0093 |
Sorafenib tosylate
|
475207-59-1
|
98%
|
|
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
|
T2056 |
VEGFR-2-IN-5
|
1430089-64-7
|
98%
|
|
VEGFR-2-IN-5 (UNC0064-12) is a patent compound in WO2013055780A1, multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
|
T2288 |
Motesanib
|
453562-69-1
|
98%
|
|
Motesanib (AMG 706) is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits...
|
T1895 |
SKLB 610
|
1125780-41-7
|
98%
|
|
SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, a...
|
T14072 |
A-443654
|
552325-16-3
|
98%
|
|
A-443654 is a pan-Akt inhibitor. A-443654 has equal potency against Akt1, Akt2, or Akt3 within cells (Ki=160 pM).
|
T21593 |
AAL-993
|
269390-77-4
|
98%
|
|
AAL-993 is a potent VEGFR inhibitor with IC50s of 130 nM, 23 nM and 18 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. AAL993 has a weak inhibitory effect on oth...
|
T4318 |
EOC317
|
939805-30-8
|
98%
|
|
EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
|
T5171 |
Treprostinil Sodium
|
289480-64-4
|
98%
|
|
Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
|
T9928 |
Ranibizumab
|
347396-82-1
|
98%
|
|
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and...
|
T9904 |
Bevacizumab
|
216974-75-3
|
98%
|
|
Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.
|
T2656 |
Fruquintinib
|
1194506-26-7
|
98%
|
|
Fruquintinib (HMPL-013) is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic...
|
T10123 |
VEGFR-2-IN-9
|
408502-06-7
|
98%
|
|
VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.
|
T4288 |
HVEGF-IN-1
|
1637443-98-1
|
98%
|
|
hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
|
T4026 |
SU5408
|
15966-93-5
|
98%
|
|
SU5408 (VEGFR2 Kinase Inhibitor I) is a potent, cell-permeable inhibitor of the VEGFR2 kinase.
|
T76866 |
Icrucumab
|
1024603-92-6
|
98%
|
|
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ...
|
T76756 |
Parsatuzumab
|
1312797-14-0
|
98%
|
|
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.Parsatuzumab selectively inhibits the interac...
|
T75163 |
GW297361
|
388627-21-2
|
98%
|
|
GW297361 is a potent inhibitor of the cell cycle protein-dependent kinase Cdk1 and also inhibits the Pho85 signaling pathway.The IC50s of GW297361 on yeast Cdk1 ...
|